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Abstract
Background: Approximately 50% of heart failure patients are readmitted to hospital within 6 months, owing to
deterioration of their condition. Thus, symptomatic treatment of heart failure requires significant improvement. The
aim of this study is to compare the effects of torasemide and furosemide on biochemical parameters of
haemodynamic and neurohormonal compensation, myocardial remodelling, clinical outcomes and quality of life in
patients with chronic heart failure.
Methods: This is a multicentre, randomized, open, blinded endpoint phase-IV trial. The study includes 120 heart
failure patients in NYHA (New York Heart Association) functional class II–IV, treated with optimal heart failure
therapy, with indications for use of loop diuretics. At enrolment, patients are stable, with a fixed dose of loop
diuretics. Patients are randomized to treatment with furosemide or torasemide (randomization 1:1). After
randomization, the current fixed dose of furosemide is continued or is replaced by an equipotential dose of
torasemide (4:1). The study consists of two control visits (3 and 6 months after enrolment) with minimal follow-up
of 6 months. Assessment involves clinical examination, Quality of Life Questionnaire, laboratory tests,
echocardiography, electrocardiography, 24 h Holter-electrocardiography monitoring, 6 -min walk test and
assessment of fluid retention. Any need for dose adjustment is assessed during the observation. The primary
objective is to compare the effects of torasemide and furosemide on clinical and biochemical parameters of
haemodynamic and neurohormonal compensation and myocardial remodelling. Secondary objectives include
monitoring of: changes in signs and symptoms of heart failure, NYHA functional class, quality of life, dosage
changes, rate of readmissions and mortality.
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Discussion: Despite decades of the diuretic’s history, knowledge about diuretic therapy is still unsatisfactory. The
most widely used diuretic, furosemide, has a stormy pharmacokinetics and pharmacodynamics, and is associated
with a high risk of mortality and hospitalization for worsening heart failure. Reports are very encouraging and
suggest beneficial effects of torasemide. Hence, there is a need for further studies of the overall effect of
torasemide, compared with furosemide. This can translate into improved quality of life and better prognosis of
patients with heart failure.
Trial registration: ClinicalTrials.gov, NCT01942109. Registered on 24 August 2013.
Keywords: Dose, Furosemide, Heart failure, Hospitalization, Loop diuretic, Prognosis, Quality of life, Randomized
controlled trial, Torasemide
Background
In developed countries, about 2% of an adult population
have heart failure, with the incidence increasing to ≥10%
among persons aged ≥70 years [1]. Despite continuous
improvement in therapy, heart failure remains a condi-
tion with a poor prognosis. Mortality in heart failure
reached 50% in a 5 year observation [1]. Decompensated
heart failure is also the most common cause of
hospitalization of adults [1]. Approximately 50% of pa-
tients with heart failure are readmitted to hospital within
6 months of discharge, owing to deterioration of their
condition [1].
Angiotensin-converting enzyme inhibitors and β-
blockers improve long-term outcomes in patients with
heart failure; according to current guidelines, these
drugs are the first-line treatment in heart failure patients
[1]. The main manifestations of heart failure worsening
are dyspnoea, reduced exercise tolerance, peripheral
oedema, orthopnoea, jugular venous distension and in-
creased nocturnal diuresis [1]. To improve symptoms
and exercise capacity in patients with heart failure,
diuretics are recommended [1]. The number of readmis-
sions related to heart failure can be reduced by proper
management of fluid retention [2]. Meta-analysis re-
vealed that diuretic-based treatment, compared with pla-
cebo, could decrease hospitalizations for worsening of
heart failure, as part of symptomatic treatment [3, 4].
Current guidelines do not emphasize superiority of any
of the available diuretics [1]. In practice, the most com-
monly used diuretic in patients with heart failure is a
loop diuretic – furosemide. Importantly, furosemide has
no positive effect on patients’ outcomes and may even
be associated with increased risk for hospitalization and
all-cause and cardiovascular mortality [5]. Therefore,
there is a need to seek a safer and more effective drug
than furosemide.
A drug with greater potential seems to be torasemide,
but so far, there is a very poor record of research into its
participation. It is postulated that, compared with fur-
osemide, torasemide reduces readmissions due to heart
failure [6]; moreover, there is a discussion of its possible
beneficial effect on mortality [7]. Yet torasemide has
been shown to have less inter- and intra-individual vari-
ation in bioavailability and longer action than furosem-
ide [8]. Vargo et al. reported that heart failure does not
affect the rate of absorption of orally administered tora-
semide, in contrast with furosemide, for which absorp-
tion was delayed [9]. Thus, torasemide has more
predictable pharmacokinetics and pharmacodynamics
and lower influence on electrolyte disorders and there-
fore has improved tolerability compared with furosemide
[10]. Torasemide also induces greater improvements in
functional and social limitations. Some clinical studies
showed improvement in New York Heart Association
(NYHA) functional class and pulmonary haemodynam-
ics, as well as reduced body weight, in patients who
received torasemide [8, 11, 12]. In a study by Müller et
al., torasemide decreased the number of mictions at 3, 6
and 12 h after diuretic intake, as well as the urgency to
urinate [11].
Diminished cardiac output, seen in heart failure, pro-
vokes the release of vasopressin and activates a renin-
angiotensin-aldosterone system [13]. Consequently, oe-
demas are produced through increased sodium and
water retention [13]. Some studies showed unfavourable
influence of furosemide on the renin-angiotensin-
aldosterone system [14, 15]. In contrast, torasemide
combines the effects of both furosemide and spironolac-
tone [16]. Therefore, torasemide may also have an anti-
androgenic effect; however, it is not fully understood
whether torasemide acts through a mineralocorticoid re-
ceptor or not [16]. It has been reported that torasemide
may block the renin-angiotensin-aldosterone system [17]
and might therefore attenuate myocardial remodelling
accompanied by left ventricular dysfunction [18]. Simul-
taneously, Lopez et al. related the use of torasemide with
decrease in cardiac fibrosis in biopsy specimens from
hypertensive patients with chronic heart failure [19].
Those additional pleiotropic effects could make torase-
mide more beneficial than furosemide.
Additionally, torasemide could be a cost-saving option
compared with furosemide. Pharmacoeconomic analysis
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shows that it reduces the overall cost of in-hospital [20]
and long-term treatment of chronic heart failure
through the reduction of hospital admissions [21]. Treat-
ment with torasemide showed 80% reduction of in-
hospital days and 30% decrease in lost working days,
compared with furosemide [22].
Only direct comparison of furosemide and torasemide
could present the similarities and differences of these two
agents. Available reports presented clinical and economic
advantages of torasemide, and at least two expert groups
recommended considering torasemide use first over fur-
osemide in heart failure patients [23, 24]. However, more
long-term data are needed to confirm these results and to
investigate the effect of torasemide on quality of life. This
report aims to describe a randomized clinical trial proto-
col designed to compare the effectiveness of torasemide
versus furosemide in improving cardiac remodelling,
haemodynamic stress and neurohormonal stress. Add-
itionally, the trial aims to assess the clinical stability, one-
year readmission rate and mortality in patients with heart
failure treated with torasemide compared with furosem-
ide. The hypothesis of this study is that torasemide may
present more favourable effects than furosemide on
biochemical and clinical parameters (e.g. biochemical bio-
markers, clinical symptoms, quality of life, long-term out-
comes) in patients with heart failure.
Methods/design
Study objectives
The primary objective of the study is to compare the
effects of torasemide and furosemide on clinical and
biochemical parameters of haemodynamic and neu-
rohormonal compensation, as well as myocardial re-
modelling in patients with chronic heart failure with
indications for use of loop diuretics.
Secondary objectives include the comparison of tora-
semide and furosemide in relation to changes in signs
and symptoms of chronic heart failure, an improvement
in NYHA functional class and quality of life, a need for
dosage changes, as well as rate of readmissions and mor-
tality in long-term observation.
Study design
The study is an investigator-initiated, multicentre, ran-
domized, open, blinded endpoint phase-IV trial with
parallel groups. The study is being carried out in two
tertiary university hospitals on cardiology wards. The
study will include 120 hospitalized patients with heart
failure. Approval was obtained from institutional review
boards. All participants must sign an informed consent
form. To reach the adequate target sample size, a list of
new admissions of patients with heart failure is checked
every day. The study protocol conforms to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 statement (Fig. 1) [25]. See Add-
itional file 1 containing the SPIRIT Checklist.
Study population
Patients included in the study are hospitalized and have
chronic heart failure in NYHA functional class II–IV.
The diagnosis of heart failure, according to current
guidelines [1], is based on clinical (typical heart failure
signs and symptoms), echocardiographic and biochem-
ical (increased concentrations of N-terminal pro-B-type
natriuretic peptide or B-type natriuretic peptide) param-
eters. Patients are treated with optimal heart failure ther-
apy and have indications for use of loop diuretics to
maintain euvolaemia. At the time of enrolment patients
are in stable condition or with exacerbation-aligned car-
diopulmonary symptoms, with a fixed dose of loop
diuretics.
Inclusion and exclusion criteria
Patients meeting all inclusion criteria and no exclusion
criteria, as shown in Table 1, are enrolled in the study.
Reasons for discontinuing or modifying allocated di-
uretics are noted (i.e., drug dose change in response to
harms, participant request, or improving or worsening
disease).
Overall study description
During hospitalization, patients with chronic heart fail-
ure who meet the inclusion criteria are asked to partici-
pate in the study. A summary of the study course is
presented in Fig. 2. Assumptions of the study are ex-
plained and informed written consent is obtained. A case
report form is created for each patient. Researchers
gather data regarding medical history, demographics,
clinical presentation, previous and current treatment,
diagnostic test results and the clinical course of index
hospitalization. During hospitalization, 12-lead electrocar-
diography, 24 h Holter-electrocardiography monitoring,
echocardiography, a 6 min walk test, and assessment of
fluid retention using a ZOE fluid status monitor are per-
formed, and blood sample is obtained for further mea-
surements of biomarkers. Patients are also asked to
complete the Quality of Life Questionnaire (SF-36v2).
Patients are randomized by investigators to treatment
with furosemide or torasemide (randomization 1:1). Pa-
tients receive a number from 001 to 120. After
randomization, the current fixed dose of furosemide is
continued or is replaced by an equipotential dose of tor-
asemide (4:1, according to the producer’s recommenda-
tions). Patients receive the proper diuretic (furosemide or
torasemide) in suitable doses at a baseline hospitalization
and then at control visits after 3 and 6 months. The short
duration of treatment, frequent control visits and ease of
study drug administration facilitate adherence. To
Balsam et al. Trials  (2017) 18:36 Page 3 of 8
maximize compliance, retention in the study and adher-
ence to treatment, patients are monitored prospectively
and routinely throughout the trial with frequent telephone
contact.
The study consists of two control visits (3 and
6 months after enrolment) with a minimal follow-up
period of 6-months. During control visits, changes in
clinical and biochemical status compared with the
baseline are monitored. Clinical examination is per-
formed for signs and symptoms of heart failure (dys-
pnoea, orthopnoea, urinary frequency, peripheral
oedema, S3 heart tone, jugular venous distension,
pulmonary rales, NYHA functional class), assessment
of exercise tolerance (6 min walk test) and fluid
retention (by measurement of a body weight and body
impedance monitor; the ZOE fluid status monitor). Based
on these tests, investigators may decide to continue the
previously established drug dose or change the dosage.
Additionally, the Quality of Life Questionnaire (SF-36v2)
will be completed, blood samples will be obtained, and
echocardiography, 12-lead electrocardiography and 24 h
Holter-electrocardiography monitoring will be performed.
Blood samples collected during baseline hospitalization
and control visits are stored in a laboratory of the univer-
sity. All blood samples will be analyzed after the end of
enrolment.
Study endpoints
Adverse events appearing after signing the informed
consent are documented. The study endpoints consist of
comparison of torasemide versus furosemide in relation
to changes in haemodynamic and neurohormonal stress,
cardiac remodelling and clinical status of heart failure
from baseline through the follow-up.
Interactions of loop diuretics with specific subgroups
will be assessed. In particular, the investigators will pro-
vide an additional analysis of influence of diuretics on
outcomes in clinically relevant subgroups, i.e. patients with
implantable devices, elderly and dilated cardiomyopathy.
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
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Assessment of outcomes
Haemodynamic and neurohormonal stress
Biochemical (N-terminal pro-B-type natriuretic peptide,
suppression of tumorigenicity 2 (ST2)), clinical (heart
rate, arterial blood pressure) and echocardiographic (left
ventricular ejection fraction, pressures in cardiac chambers)
parameters, considered to be associated with increased
haemodynamic and neurohormonal stress [26, 27] are mea-
sured. Blood samples are collected and echocardiographic
studies are performed at the baseline and control visits.
Cardiac remodelling
Cardiac remodelling is evaluated in terms of changes in con-
centrations of biomarkers and echocardiographic parame-
ters. Biomarkers responsible for myocardial fibrosis, necrosis
and inflammation (Galectin-3, ST2, high-sensitive troponin
T, collagen peptides, metalloproteinases) are considered
[28–30]. During echocardiographic study, the left ventricular
end-diastolic dimension, left ventricular end-systolic dimen-
sion, intraventricular septum and posterior wall thickness,
left ventricular mass index, left ventricular ejection fraction,
valve flows, and right ventricular and atrial dimensions will
be measured). Blood samples are collected and echocardiog-
raphy is performed at the baseline and control visits.
Table 1 Inclusion and exclusion criteria
Inclusion criteria:
Signed informed consent form
Age ≥18 years
Patients with chronic heart failure, as defined by the European Society
of Cardiology (update 2016)
New York Heart Association (NYHA) functional class II–IV
Patients who require diuretic therapy for maintain euvolaemia







Serum potassium >6.0 mmol/l
Serum creatinine >2.5 mg/dl
Malignancy
Life expectancy <1 year
Planned valve surgery or heart transplantation
Fig. 2 Study design as flow diagram: recruitment, randomization, intervention, follow-up, assessment and outcomes. CHF, chronic heart failure;
NYHA, New York Heart Association
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Clinical status of heart failure
An important element of the study is to evaluate changes
in clinical status of heart failure and outcomes in long-
term observation, in both groups – furosemide and
torasemide. The composite endpoint measures include
changes in signs and symptoms of chronic heart failure
(heart rate, arterial blood pressure, NYHA functional class
change, distance covered in 6 min walk test, electrocardi-
ography recordings). Additional endpoint measures are
need for intensification of diuretics dosage, changes in la-
boratory tests (ionogram, renal function, biochemical
profile), rate of readmissions or death owing to heart
failure worsening, presence of other adverse events (i.e.
myocardial infarction, thromboembolic events), changes
in quality of life (based on the Quality of Life Question-
naire (SF-36v2) [31]), the presence or exacerbation of
atrial or ventricular arrhythmias (12-lead electrocardiog-
raphy, 24 h Holter monitoring) and assessment of fluid
retention (presence of peripheral oedema, measurement
of body weight and body impedance). Body impedance is
measured using a ZOE fluid status monitor, which is a
device determining the level of fluid retention on the basis
of the resistance (impedance in ohms) of the human body.
The less the impedance, the more hydrated is the body.
The same model of case report form is used at baseline
and follow-up visits.
Data management and archiving
All data are coded and stored on university password-
protected computers. Any physical copies of the case
report forms and all study-related documents are ar-
chived at the university. All data are checked monthly by
investigators (MG, KJF, GO) to ensure that all protocols
and ethical guidelines for data collection and analysis are
followed.
Power analysis
The study is designed to detect a 50% reduction of
primary endpoint prevalence between the groups. Under
the assumption that death and rehospitalization are
relatively common in patients with heart failure, we
estimate the frequency of primary endpoint in the fur-
osemide group as 60% [32]. Sample size calculation was
performed for 5% type I error rate with 70% power.
The total number of events needed in study group to
attain 70% power with an alpha of 0.05, is 54. To achieve
this number of events, we plan to recruit 120 patients.
Statistical analysis
Fisher’s exact test and the Mann–Whitney U test will be
performed for comparison of both groups, for categor-
ical variables and continuous variables, respectively. To
determine the risk factors of primary and secondary
endpoints, logistic regression analysis or the Cox
proportional hazards regression model will be per-
formed. To assess the independent influence of study
drug on the outcome, multivariate logistic regression
analysis will be performed. Statistical significance will be
considered for P < 0.05 for all tests. Statistical analysis
will be performed using SAS software, version 9.4.
Limitations of the study
The study is not a double-blind trial; this might have
some impact on the results. Moreover, the small number
of participants will probably not enable assessment of
the impact of torasemide and furosemide in different
clinically relevant subgroups i.e. elderly, patients with
chronic kidney disease, dilated cardiomyopathy. The
relatively small sample size might not show the clinical
benefits associated with torasemide for hard cardiovas-
cular events. However, if an improvement in clinical
condition and fluid retention is demonstrated, we feel
that this might have a positive effect in the treatment of
heart failure patients.
Data monitoring and auditing
Study participants are closely monitored by the investi-
gators. Case report forms are used to record any sus-
pected harms of the study treatment. Study participants
may be withdrawn from the study if there is suspicion of
treatment harm (e.g. worsening renal function, allergic
reaction). Monitoring of the data and quality of the
study is performed by the senior-investigators (GO and
KJF) who compose a data monitoring committee.
Discussion
The currently available data suggest that torasemide may
be a better alternative for treatment of congestion in
chronic heart failure than furosemide.
However, answers to many questions about the super-
iority and usefulness of torasemide are still missing. The
hypothesis of this study assumes that torasemide may
present more favourable effects than furosemide on bio-
chemical and clinical parameters of haemodynamic
stress, cardiac remodelling, as well as clinical symptoms,
quality of life and long-term outcomes in patients with
heart failure.
If a reduction in haemodynamic and neurohormonal
stress, as well as cardiac remodelling is demonstrated, this
may prove additional advantages of torasemide compared
with furosemide. This study might add valuable informa-
tion about torasemide, supporting its more frequent use.
Trial status
At the time of the manuscript submission, 50 patients
were enrolled in the study and 16 of them had finished
the follow-up. We expect to finish the study in 2017.
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